MedTrace Logo

Study of BCMA CAR-T in Multiple Myeloma

NCT03559764 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-06-18

No results posted yet for this study

Summary

This is a single centre、single arm、open-label，to investigate the safety and efficacy of anti-BCMA CAR T cells in patients with Relapsed and Refractory multiple myeloma.

Conditions

  • Relapsed and Refractory Multiple Myeloma

Interventions

BIOLOGICAL

Anti-BCMA CAR T cells

Transparent colorless or slightly yellow liquid

Sponsors & Collaborators

  • Allife Medical Science and Technology Co., Ltd.

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-30
Primary Completion
2020-02-29
Completion
2020-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03559764 on ClinicalTrials.gov